Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Finn

Showing results (391-400 of 527) with videos related to

Pageof 53
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 13, 2013
Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancerEdward B Garon, Richard J Pietras, Richard S Finn, et al.
Breast Cancer Research and Treatment|October 5, 2013
AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53Ondrej Kalous, Dylan Conklin, Amrita J Desai, et al.
Breast (Edinburgh, Scotland)|December 4, 2022
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3Hope S Rugo, Seock-Ah Im, Anil A Joy, et al.
Hepatology (Baltimore, Md.)|May 21, 2020
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus ConferenceJosep M Llovet, Augusto Villanueva, Jorge A Marrero, et al.
Journal of the National Cancer Institute|July 23, 2018
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast CancerVéronique Diéras, Hope S Rugo, Patrick Schnell, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE studyY J Kim, P Merle, R S Finn, et al.
Liver Cancer|February 20, 2020
Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular CarcinomaAngel Alsina, Masatoshi Kudo, Arndt Vogel, et al.
Breast Cancer Research and Treatment|July 20, 2020
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18)Richard S Finn, Katalin Boer, Igor Bondarenko, et al.
Breast Cancer Research and Treatment|August 13, 2020
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trialsRichard S Finn, Massimo Cristofanilli, Johannes Ettl, et al.
Movement Ecology|February 7, 2026
Miniaturized light-level geolocators provide novel insight into the migration ecology of an endangered songbirdJohn N Macey, Jane M Kunberger, Kellene Collins, et al.
Pageof 53

Showing results (391-400 of 527) with videos related to

Sort By:
Pageof 53
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 13, 2013
Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancerEdward B Garon, Richard J Pietras, Richard S Finn, et al.
Breast Cancer Research and Treatment|October 5, 2013
AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53Ondrej Kalous, Dylan Conklin, Amrita J Desai, et al.
Breast (Edinburgh, Scotland)|December 4, 2022
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3Hope S Rugo, Seock-Ah Im, Anil A Joy, et al.
Hepatology (Baltimore, Md.)|May 21, 2020
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus ConferenceJosep M Llovet, Augusto Villanueva, Jorge A Marrero, et al.
Journal of the National Cancer Institute|July 23, 2018
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast CancerVéronique Diéras, Hope S Rugo, Patrick Schnell, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE studyY J Kim, P Merle, R S Finn, et al.
Liver Cancer|February 20, 2020
Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular CarcinomaAngel Alsina, Masatoshi Kudo, Arndt Vogel, et al.
Breast Cancer Research and Treatment|July 20, 2020
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18)Richard S Finn, Katalin Boer, Igor Bondarenko, et al.
Breast Cancer Research and Treatment|August 13, 2020
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trialsRichard S Finn, Massimo Cristofanilli, Johannes Ettl, et al.
Movement Ecology|February 7, 2026
Miniaturized light-level geolocators provide novel insight into the migration ecology of an endangered songbirdJohn N Macey, Jane M Kunberger, Kellene Collins, et al.
Pageof 53